NCT05300542 is a NA clinical trial of Topical Cream with 0.5% Active in Erythema, sponsored by Amazentis SA.

Who is sponsoring NCT05300542?

NCT05300542 is sponsored by Amazentis SA.

What drugs are being tested in NCT05300542?

Interventions in NCT05300542: Topical Placebo Cream, Topical Cream with 0.5% Active, Topical Cream with 1% Active.

What condition does NCT05300542 study?

NCT05300542 studies Erythema, Sun Damaged Skin, Skin Inflammation.

Is NCT05300542 still recruiting?

NCT05300542 is currently completed. Last updated 6 April 2023.

Last reviewed 2023-04-06 · How we verify

NCT05300542

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy Study of a Novel Skin Health Product to Reduce an UVB Induced Erythema

Completed NA Last updated 6 April 2023

What this trial tests

NA trial testing Topical Placebo Cream in Erythema in 22 participants. Completed in 13 April 2022.

Timeline

17 March 2022

Primary endpoint
31 March 2022

13 April 2022

Quick facts

Lead sponsor	Amazentis SA
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	basic science
Enrollment	22
Start date	17 March 2022
Primary completion	31 March 2022
Estimated completion	13 April 2022
Sites	1 location across Germany

Drugs / interventions tested

Topical Placebo Cream
Topical Cream with 0.5% Active
Topical Cream with 1% Active

Conditions studied

Erythema — all drugs for Erythema →
Sun Damaged Skin — all drugs for Sun Damaged Skin →
Skin Inflammation — all drugs for Skin Inflammation →

Sponsor

Amazentis SA — full company profile →

Who can join

Adults 18 to 65, any sex, with Erythema or Sun Damaged Skin. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to determine the erythema-reducing efficacy of a test product in two concentrations on a light sunburn induced by a sun simulator compared to an untreated control and a placebo product.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Topical application of Urolithin A slows intrinsic skin aging and protects from UVB-mediated photodamage: Findings from Randomized Clinical Trials
D’Amico D, Fouassier A, Faitg J, Hennighausen N, et al · · 2023 · DOI 10.1101/2023.06.16.23291378

Verify or expand the search:

Other recruiting trials for Erythema

Currently open trials in the same condition.

NCT07474883 — Efficacy of 0.5% Topical Timolol Eye Drops in the Treatment of Post-Inflammatory Erythema Following Acne Vulgaris · EARLY_PHASE1 · recruiting
NCT02876107 — Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer · Phase 2 · active not recruiting
NCT02411656 — Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative B · Phase 2 · active not recruiting

Other Amazentis SA trials

Trials by the same sponsor.

NCT07517913 — Cerebrospinal Fluid Kinetics of Urolithin A · NA · not yet recruiting
NCT07517874 — Human Skin Safety Testing of 1 Mitopure Topical Products Using a Human Repeat Insult Patch Test (HRIPT) in Healthy Volun · NA · not yet recruiting
NCT07517887 — Anti-aging Efficacy Study on One Cosmetic Product Containing Mitopure · NA · not yet recruiting
NCT07517900 — Human Skin Safety Testing of 1 Mitopure Topical Product Using a Clinical Safety in Use Study in Healthy Volunteers · NA · not yet recruiting
NCT07231783 — The Effect of Urolithin A (Mitopure®) Supplementation on Muscle Strength in Healthy Middle-Aged Adults · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05300542 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Amazentis SA
Last refreshed: 6 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05300542.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing